Header Logo

SANJAY MATHEW

TitleProfessor
InstitutionBaylor College of Medicine
DepartmentDepartment of Psychiatry & Behavioral Sciences
Address1977 BUTLER BOULEVARD
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R01MH136178     (MATHEW, SANJAY J)Jul 18, 2024 - May 31, 2029
    NIH
    2/2 A brief automated neurocognitive training to enhance the real-world impact of ketamine's rapid antidepressant effect
    Role: Principal Investigator
    R21MH133198     (MATHEW, SANJAY J)Jan 1, 2024 - Dec 31, 2025
    NIH
    Gamma oscillations as a prognostic marker for ketamine therapy in treatment resistant depression
    Role: Principal Investigator
    R61MH110540     (MATHEW, SANJAY J)Sep 21, 2016 - Jan 31, 2021
    NIH
    NMDA receptor modulation for hyperarousal in PTSD
    Role: Principal Investigator
    I01CX001205     (MATHEW, SANJAY J)Oct 1, 2015 - Mar 31, 2021
    NIH
    Ketamine for Treatment Resistant Late-Life Depression
    Role: Principal Investigator
    R01MH085054     (MATHEW, SANJAY J)Aug 1, 2010 - Apr 30, 2015
    NIH
    2/3-Efficacy and Tolerability of Riluzole in Treatment-Resistant Depression
    Role: Principal Investigator
    R01MH081870     (MATHEW, SANJAY J)Jul 23, 2009 - Jul 30, 2014
    NIH
    Optimization of IV Ketamine for Treatment Resistant Major Depression
    Role: Principal Investigator
    K23MH069656     (MATHEW, SANJAY J)Sep 1, 2004 - Aug 31, 2010
    NIH
    PROTON MRS STUDIES IN GENERALIZED ANXIETY DISORDER
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Kabotyanski KE, Yi HG, Hingorani R, Robinson BS, Cowley HP, Fifer MS, Wester BA, Lamichhane B, Sabharwal A, Allawala AB, Rajesh SV, Diab N, Mathura RK, Pirtle V, Adkinson J, Watrous AJ, Bartoli E, Xiao J, Banks GP, Mathew SJ, Goodman WK, Pitkow X, Pouratian N, Hayden BY, Provenza NR, Sheth SA. Towards objective, temporally resolved neurobehavioral predictors of emotional state. Brain Stimul. 2024 Oct 18; 17(6):1208-1212. PMID: 39427985.
      Citations:    Fields:    
    2. Hossein S, Woody ML, Panny B, Spotts C, Wallace ML, Mathew SJ, Howland RH, Price RB. Functional connectivity subtypes during a positive mood induction: Predicting clinical response in a randomized controlled trial of ketamine for treatment-resistant depression. J Psychopathol Clin Sci. 2024 Sep 23. PMID: 39311825.
      Citations:    Fields:    
    3. Reddy S, Kabotyanski KE, Hirani S, Liu T, Naqvi Z, Giridharan N, Hasen M, Provenza NR, Banks GP, Mathew SJ, Goodman WK, Sheth SA, Reddy S, Kabotyanski KE, Hirani S, Liu T, Naqvi Z, Giridharan N, Hasen M, Provenza NR, Banks GP, Mathew SJ, Goodman WK, Sheth SA. Efficacy of Deep Brain Stimulation for Treatment-Resistant Depression: Systematic Review and Meta-Analysis. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024 Aug 26. PMID: 39197490.
      Citations:    Fields:    
    4. Myers J, Xiao J, Mathura R, Shofty B, Pirtle V, Adkinson J, Allawala AB, Anand A, Gadot R, Najera R, Rey HG, Mathew SJ, Bijanki K, Banks G, Watrous A, Bartoli E, Heilbronner SR, Provenza N, Goodman WK, Pouratian N, Hayden BY, Sheth SA. Intracranial Directed Connectivity Links Subregions of the Prefrontal Cortex to Major Depression. medRxiv. 2024 Aug 08. PMID: 39148826; PMCID: PMC11326344.
      Citations:    
    5. Xiao J, Adkinson JA, Myers J, Allawala AB, Mathura RK, Pirtle V, Najera R, Provenza NR, Bartoli E, Watrous AJ, Oswalt D, Gadot R, Anand A, Shofty B, Mathew SJ, Goodman WK, Pouratian N, Pitkow X, Bijanki KR, Hayden B, Sheth SA. Beta activity in human anterior cingulate cortex mediates reward biases. Nat Commun. 2024 Jul 15; 15(1):5528. PMID: 39009561; PMCID: PMC11250824.
      Citations: 1     Fields:    Translation:Humans
    6. Xiao J, Adkinson JA, Allawala AB, Banks G, Bartoli E, Fan X, Mocchi M, Pascuzzi B, Pulapaka S, Franch MC, Mathew SJ, Mathura RK, Myers J, Pirtle V, Provenza NR, Shofty B, Watrous AJ, Pitkow X, Goodman WK, Pouratian N, Sheth S, Bijanki KR, Hayden BY. Insula uses overlapping codes for emotion in self and others. bioRxiv. 2024 Jun 08. PMID: 38895233; PMCID: PMC11185604.
      Citations: 1     
    7. Kabotyanski KE, Najera RA, Banks GP, Sharma H, Provenza NR, Hayden BY, Mathew SJ, Sheth SA. Cost-effectiveness and threshold analysis of deep brain stimulation vs. treatment-as-usual for treatment-resistant depression. Transl Psychiatry. 2024 Jun 07; 14(1):243. PMID: 38849334; PMCID: PMC11161481.
      Citations: 1     Fields:    Translation:Humans
    8. Jha MK, Wilkinson ST, Krishnan K, Collins KA, Sanacora G, Murrough J, Goes F, Altinay M, Aloysi A, Asghar-Ali A, Barnett B, Chang L, Costi S, Malone D, Nikayin S, Nissen SE, Ostroff R, Reti I, Wolski K, Wang D, Hu B, Mathew SJ, Anand A. Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024 Jun 03; 7(6):e2417786. PMID: 38916891; PMCID: PMC11200139.
      Citations:    Fields:    Translation:Humans
    9. Eken HN, Spotts C, Panny B, Griffo A, Degutis M, Cruz N, Bell E, Do-Nguyen K, Wallace ML, Mathew SJ, Howland RH, Price RB. Improved implicit self-esteem is associated with extended antidepressant effects following a novel synergistic intervention. Mol Psychiatry. 2024 Nov; 29(11):3431-3439. PMID: 38755245.
      Citations:    Fields:    
    10. Allawala AB, Bijanki KR, Adkinson J, Oswalt D, Tsolaki E, Mathew S, Mathura RK, Bartoli E, Provenza N, Watrous AJ, Xiao J, Pirtle V, Mocchi MM, Rajesh S, Diab N, Cohn JF, Borton DA, Goodman WK, Pouratian N, Sheth SA. Stereo-Electroencephalography-Guided Network Neuromodulation for Psychiatric Disorders: The Neurophysiology Monitoring Unit. Oper Neurosurg (Hagerstown). 2024 Sep 01; 27(3):329-336. PMID: 39145663; PMCID: PMC11315541.
      Citations:    Fields:    Translation:Humans
    11. Papakostas GI, Trivedi MH, Shelton RC, Iosifescu DV, Thase ME, Jha MK, Mathew SJ, DeBattista C, Dokucu ME, Brawman-Mintzer O, Currier GW, McCall WV, Modirrousta M, Macaluso M, Bystritsky A, Rodriguez FV, Nelson EB, Yeung AS, Feeney A, MacGregor LC, Carmody T, Fava M. Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial. Mol Psychiatry. 2024 Aug; 29(8):2287-2295. PMID: 38454079; PMCID: PMC11412904.
      Citations:    Fields:    Translation:Humans
    12. Allawala A, Bijanki KR, Oswalt D, Mathura RK, Adkinson J, Pirtle V, Shofty B, Robinson M, Harrison MT, Mathew SJ, Goodman WK, Pouratian N, Sheth SA, Borton DA. Prefrontal network engagement by deep brain stimulation in limbic hubs. Front Hum Neurosci. 2023; 17:1291315. PMID: 38283094; PMCID: PMC10813208.
      Citations: 2     
    13. Rengasamy M, Mathew S, Howland R, Griffo A, Panny B, Price R. Neural connectivity moderators and mechanisms of ketamine treatment among treatment-resistant depressed patients: a?randomized controlled trial. EBioMedicine. 2024 Jan; 99:104902. PMID: 38141395; PMCID: PMC10788398.
      Citations: 1     Fields:    Translation:HumansAnimals
    14. Sheth SA, Shofty B, Allawala A, Xiao J, Adkinson JA, Mathura RK, Pirtle V, Myers J, Oswalt D, Provenza NR, Giridharan N, Noecker AM, Banks GP, Gadot R, Najera RA, Anand A, Devara E, Dang H, Bartoli E, Watrous A, Cohn J, Borton D, Mathew SJ, McIntyre CC, Goodman W, Bijanki K, Pouratian N. Stereo-EEG-guided network modulation for psychiatric disorders: Surgical considerations. Brain Stimul. 2023 Nov-Dec; 16(6):1792-1798. PMID: 38135358; PMCID: PMC10787578.
      Citations:    Fields:    Translation:Humans
    15. Mathew SJ, Jha MK, Anand A. Choosing Between Ketamine and Electroconvulsive Therapy for Outpatients With Treatment-Resistant Depression-Advantage Ketamine? JAMA Psychiatry. 2023 12 01; 80(12):1187-1188. PMID: 37878334.
      Citations:    Fields:    Translation:Humans
    16. O'Brien B, Lee J, Kim S, Nandra GS, Pannu P, Tamman A, Amarneh D, Swann AC, Murphy N, Averill L, Jha M, Mathew SJ. Anti-suicidal effects of IV ketamine in a real-world setting. Psychiatry Res. 2024 Jan; 331:115604. PMID: 38064911.
      Citations:    Fields:    Translation:Humans
    17. Parikh SV, Aaronson ST, Mathew SJ, Alva G, DeBattista C, Kanes S, Lasser R, Bullock A, Kotecha M, Jung J, Forrestal F, Jonas J, Vera T, Leclair B, Doherty J. Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study. Neuropsychopharmacology. 2024 Jan; 49(2):467-475. PMID: 37875578; PMCID: PMC10724299.
      Citations: 1     Fields:    Translation:Humans
    18. Murphy N, Tamman AJF, Lijffijt M, Amarneh D, Iqbal S, Swann A, Averill LA, O'Brien B, Mathew SJ. Correction: Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial. Neuropsychopharmacology. 2023 Oct; 48(11):1699. PMID: 37349477; PMCID: PMC10517107.
      Citations:    Fields:    
    19. Anand A, Mathew SJ, Hu B. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. Reply. N Engl J Med. 2023 Sep 07; 389(10):961-962. PMID: 37672705.
      Citations:    Fields:    Translation:Humans
    20. Nierenberg A, Lavin P, Javitt DC, Shelton R, Sapko MT, Mathew S, Besthof RE, Javitt JC. NRX-101 (D-cycloserine plus lurasidone) vs. lurasidone for the maintenance of initial stabilization after ketamine in patients with severe bipolar depression with acute suicidal ideation and behavior: a randomized prospective phase 2 trial. Int J Bipolar Disord. 2023 Aug 13; 11(1):28. PMID: 37573534; PMCID: PMC10423711.
      Citations:    
    21. Darrow SM, Pizzagalli DA, Smoski M, Mathew SJ, Nurnberger J, Lisanby SH, Iosifescu D, Murrough JW, Yang H, Weiner RD, Sanacora G, Keefe RSE, Song A, Goodman W, Potter WZ, Krystal AD, Whitton AE. Using latent profile analyses to classify subjects with anhedonia based on reward-related measures obtained in the FAST-MAS study. J Affect Disord. 2023 10 15; 339:584-592. PMID: 37467805.
      Citations:    Fields:    Translation:Humans
    22. Schatzberg AF, Mathew SJ. The why, when, where, how, and so what of so-called rapidly acting antidepressants. Neuropsychopharmacology. 2024 Jan; 49(1):189-196. PMID: 37460770; PMCID: PMC10700639.
      Citations:    Fields:    Translation:Humans
    23. Mathew SJ, Jean-Lys S, Phull R, Yarasani R. Characterization of Extended-Release Lorazepam: Pharmacokinetic Results Across Phase 1 Clinical Studies. J Clin Psychopharmacol. 2023 Jul-Aug 01; 43(4):350-360. PMID: 37335199; PMCID: PMC10309101.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    24. Anand A, Mathew SJ, Sanacora G, Murrough JW, Goes FS, Altinay M, Aloysi AS, Asghar-Ali AA, Barnett BS, Chang LC, Collins KA, Costi S, Iqbal S, Jha MK, Krishnan K, Malone DA, Nikayin S, Nissen SE, Ostroff RB, Reti IM, Wilkinson ST, Wolski K, Hu B. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. N Engl J Med. 2023 Jun 22; 388(25):2315-2325. PMID: 37224232.
      Citations: 15     Fields:    Translation:Humans
    25. Kopelman J, Keller TA, Panny B, Griffo A, Degutis M, Spotts C, Cruz N, Bell E, Do-Nguyen K, Wallace ML, Mathew SJ, Howland RH, Price RB. Rapid neuroplasticity changes and response to intravenous ketamine: a randomized controlled trial in treatment-resistant depression. Transl Psychiatry. 2023 05 09; 13(1):159. PMID: 37160885; PMCID: PMC10170140.
      Citations: 1     Fields:    Translation:HumansAnimals
    26. Price RB, Wallace ML, Mathew SJ, Howland RH. One-Year Outcomes Following Intravenous Ketamine Plus Digital Training Among Patients with Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2023 05 01; 6(5):e2312434. PMID: 37155171; PMCID: PMC10167566.
      Citations:    Fields:    Translation:Humans
    27. Murphy N, Tamman AJF, Lijffijt M, Amarneh D, Iqbal S, Swann A, Averill LA, O'Brien B, Mathew SJ. Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial. Neuropsychopharmacology. 2023 10; 48(11):1586-1593. PMID: 37076582; PMCID: PMC10516885.
      Citations:    Fields:    Translation:Humans
    28. Vas C, Jain A, Trivedi M, Jha MK, Mathew SJ. Pharmacotherapy for Treatment-Resistant Depression: Antidepressants and Atypical Antipsychotics. Psychiatr Clin North Am. 2023 06; 46(2):261-275. PMID: 37149344.
      Citations: 1     Fields:    Translation:Humans
    29. Jha MK, Mathew SJ. Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape. Am J Psychiatry. 2023 03 01; 180(3):190-199. PMID: 36855876.
      Citations: 1     Fields:    Translation:Humans
    30. Xiao J, Provenza NR, Asfouri J, Myers J, Mathura RK, Metzger B, Adkinson JA, Allawala AB, Pirtle V, Oswalt D, Shofty B, Robinson ME, Mathew SJ, Goodman WK, Pouratian N, Schrater PR, Patel AB, Tolias AS, Bijanki KR, Pitkow X, Sheth SA. Decoding Depression Severity From Intracranial Neural Activity. Biol Psychiatry. 2023 09 15; 94(6):445-453. PMID: 36736418; PMCID: PMC10394110.
      Citations: 1     Fields:    Translation:Humans
    31. Carreon RL, Rivas-Grajales AM, Murphy N, Mathew SJ, Jha MK. Biomarkers in Psychiatric Drug Development: From Precision Medicine to Novel Therapeutics. Adv Neurobiol. 2023; 30:287-297. PMID: 36928855.
      Citations:    Fields:    Translation:Humans
    32. Hock RS, Feeney A, Iovieno N, Murrough JW, Mathew SJ, Iosifescu DV, Fava M, Jha MK, Papakostas GI. Rapidity of Symptom Improvement With Intranasal Esketamine for Major Depressive Disorder: A Systematic Review and Meta-Analysis. J Clin Psychiatry. 2022 12 12; 84(1). PMID: 36516320.
      Citations:    Fields:    Translation:Humans
    33. Feeney A, Hoeppner BB, Freeman MP, Flynn M, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, DeBattista C, Ionescu DF, Cusin C, Papakostas GI, Jha MK, Fava M. Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study. J Clin Psychiatry. 2022 11 14; 84(1). PMID: 36383742.
      Citations: 2     Fields:    Translation:Humans
    34. Bloomfield-Clagett B, Ballard ED, Greenstein DK, Wilkinson ST, Grunebaum MF, Murrough JW, Mathew SJ, Phillips JL, Fava M, Sanacora G, Zarate CA. A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Nonsuicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine. Int J Neuropsychopharmacol. 2022 10 25; 25(10):827-838. PMID: 35994774; PMCID: PMC9593215.
      Citations:    
    35. O'Brien B, Lee J, Kim S, Nandra GS, Pannu P, Swann AC, Murphy N, Tamman AJF, Amarneh D, Lijffijt M, Averill LA, Mathew SJ. Replication of distinct trajectories of antidepressant response to intravenous ketamine. J Affect Disord. 2023 01 15; 321:140-146. PMID: 36302492.
      Citations: 1     Fields:    Translation:Humans
    36. Price RB, Spotts C, Panny B, Griffo A, Degutis M, Cruz N, Bell E, Do-Nguyen K, Wallace ML, Mathew SJ, Howland RH. A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial. Am J Psychiatry. 2022 12 01; 179(12):959-968. PMID: 36128684; PMCID: PMC9722511.
      Citations:    
    37. Price RB, Kissel N, Baumeister A, Rohac R, Woody ML, Ballard ED, Zarate CA, Deakin W, Abdallah CG, Feder A, Charney DS, Grunebaum MF, Mann JJ, Mathew SJ, Gallagher B, McLoughlin DM, Murrough JW, Muthukumaraswamy S, McMillan R, Sumner R, Papakostas G, Fava M, Hock R, Phillips JL, Blier P, Shiroma P, ?? P, Su TP, Chen MH, Tiger M, Lundberg J, Wilkinson ST, Wallace ML. International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators. Mol Psychiatry. 2022 12; 27(12):5096-5112. PMID: 36071111; PMCID: PMC9763119.
      Citations:    
    38. O'Brien B, Wilkinson ST, Mathew SJ. An Update on Community Ketamine Practices. Am J Psychiatry. 2022 05; 179(5):393-394. PMID: 35491568.
      Citations:    Fields:    Translation:Humans
    39. Poblete G, Nguyen T, Gosnell S, Sofela O, Patriquin M, Mathew SJ, Swann A, Nielsen DA, Kosten TR, Salas R. A Novel Approach to Link Genetics and Human MRI Identifies AKAP7-Dependent Subicular/Prefrontal Functional Connectivity as Altered in Suicidality. Chronic Stress (Thousand Oaks). 2022 Jan-Dec; 6:24705470221083700. PMID: 35340866; PMCID: PMC8941704.
      Citations:    
    40. Shepard CA, Rufino KA, Lee J, Tran T, Paddock K, Wu C, Oldham JM, Mathew SJ, Patriquin MA. Nighttime Sleep Quality and Daytime Sleepiness Predicts Suicide Risk in Adults Admitted to an Inpatient Psychiatric Hospital. Behav Sleep Med. 2023 Mar-Apr; 21(2):129-141. PMID: 35296204.
      Citations:    Fields:    
    41. Tamman A, Anand A, Mathew SJ. A comparison of the safety, feasibility, and tolerability of ECT and ketamine for treatment-resistant depression. Expert Opin Drug Saf. 2022 Jun; 21(6):745-759. PMID: 35253555.
      Citations:    Fields:    Translation:Humans
    42. Kritzer MD, Mischel NA, Young JR, Lai CS, Masand PS, Szabo ST, Mathew SJ. Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress. Ann Clin Psychiatry. 2022 02; 34(1):33-43. PMID: 35166663; PMCID: PMC9044467.
      Citations: 1     Fields:    Translation:Humans
    43. Murphy N, Lijffijt M, Ramakrishnan N, Vo-Le B, Vo-Le B, Iqbal S, Iqbal T, O'Brien B, Smith MA, Swann AC, Mathew SJ. Does mismatch negativity have utility for NMDA receptor drug development in depression? Braz J Psychiatry. 2022 Jan-Feb; 44(1):61-73. PMID: 33825765; PMCID: PMC8827377.
      Citations: 1     Fields:    Translation:HumansAnimals
    44. Lijffijt M, Murphy N, Iqbal S, Green CE, Iqbal T, Chang LC, Haile CN, Hirsch LC, Ramakrishnan N, Fall DA, Swann AC, Al Jurdi RK, Mathew SJ. Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial. Neuropsychopharmacology. 2022 04; 47(5):1088-1095. PMID: 34839364; PMCID: PMC8938498.
      Citations:    Fields:    Translation:Humans
    45. Sheth SA, Bijanki KR, Metzger B, Allawala A, Pirtle V, Adkinson JA, Myers J, Mathura RK, Oswalt D, Tsolaki E, Xiao J, Noecker A, Strutt AM, Cohn JF, McIntyre CC, Mathew SJ, Borton D, Goodman W, Pouratian N. Deep Brain Stimulation for Depression Informed by Intracranial Recordings. Biol Psychiatry. 2022 08 01; 92(3):246-251. PMID: 35063186; PMCID: PMC9124238.
      Citations:    Fields:    Translation:Humans
    46. Rivas-Grajales AM, Mathew SJ, Rodgers JJ. A Case of Intranasal Ketamine Misuse: Considerations for Clinical Practice. J Psychiatr Pract. 2021 11 05; 27(6):492-495. PMID: 34768275.
      Citations:    Fields:    Translation:Humans
    47. Pizzagalli DA, Smoski M, Ang YS, Whitton AE, Sanacora G, Mathew SJ, Nurnberger J, Lisanby SH, Iosifescu DV, Murrough JW, Yang H, Weiner RD, Calabrese JR, Goodman W, Potter WZ, Krystal AD. Correction to: Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS). Neuropsychopharmacology. 2021 Nov; 46(12):2224. PMID: 34389811; PMCID: PMC8505431.
      Citations:    Fields:    
    48. Ramakrishnan N, Lijffijt M, Green CE, Balderston NL, Murphy N, Grillon C, Iqbal T, Vo-Le B, O'Brien B, Murrough JW, Swann AC, Mathew SJ. Neurophysiological and clinical effects of the NMDA receptor antagonist lanicemine (BHV-5500) in PTSD: A randomized, double-blind, placebo-controlled trial. Depress Anxiety. 2021 11; 38(11):1108-1119. PMID: 34254405; PMCID: PMC8560553.
      Citations: 1     Fields:    Translation:Humans
    49. Iovieno N, Papakostas GI, Feeney A, Fava M, Mathew SJ, Iosifescu DI, Murrough JW, Macaluso M, Hock RS, Jha MK. Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset. J Clin Psychiatry. 2021 06 15; 82(4). PMID: 34133089.
      Citations: 2     Fields:    Translation:Humans
    50. Feeney A, Hock RS, Freeman MP, Flynn M, Hoeppner B, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Fava M, Papakostas GI. The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study. Eur Neuropsychopharmacol. 2021 08; 49:122-132. PMID: 34090255; PMCID: PMC8338746.
      Citations: 2     Fields:    Translation:Humans
    51. Rivas-Grajales AM, Salas R, Robinson ME, Qi K, Murrough JW, Mathew SJ. Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression. Int J Neuropsychopharmacol. 2021 05 18; 24(5):383-391. PMID: 33249434; PMCID: PMC8130203.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    52. O'Brien B, Lijffijt M, Lee J, Kim YS, Wells A, Murphy N, Ramakrishnan N, Swann AC, Mathew SJ. Distinct trajectories of antidepressant response to intravenous ketamine. J Affect Disord. 2021 05 01; 286:320-329. PMID: 33770540.
      Citations: 1     Fields:    Translation:Humans
    53. Costi S, Morris LS, Kirkwood KA, Hoch M, Corniquel M, Vo-Le B, Iqbal T, Chadha N, Pizzagalli DA, Whitton A, Bevilacqua L, Jha MK, Ursu S, Swann AC, Collins KA, Salas R, Bagiella E, Parides MK, Stern ER, Iosifescu DV, Han MH, Mathew SJ, Murrough JW. Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial. Am J Psychiatry. 2021 05 01; 178(5):437-446. PMID: 33653118; PMCID: PMC8791195.
      Citations: 3     Fields:    Translation:Humans
    54. Czamara D, Tissink E, Tuhkanen J, Martins J, Awaloff Y, Drake AJ, Khulan B, Palotie A, Nemeroff CB, Craighead WE, Dunlop BW, Mayberg HS, Kinkead B, Mathew SJ, Iosifescu DV, Neylan TC, Lahti J, Eriksson JG, Ressler KJ, Binder EB, Winter SM, Heim CM, R?ikk?nen K, Proven?al N. Combined effects of genotype and childhood adversity shape variability of DNA methylation across age. Transl Psychiatry. 2021 02 01; 11(1):88. PMID: 33526782; PMCID: PMC7851167.
      Citations: 7     Fields:    Translation:HumansCells
    55. Johnson C, Mathew SJ, Oh H, Rufino KA, Najafi B, Colombo AE, Patriquin MA. Wearable technology: A promising opportunity to improve inpatient psychiatry safety and outcomes. J Psychiatr Res. 2021 03; 135:104-106. PMID: 33465608.
      Citations:    Fields:    Translation:Humans
    56. Murphy N, Ramakrishnan N, Vo-Le B, Vo-Le B, Smith MA, Iqbal T, Swann AC, Mathew SJ, Lijffijt M. A randomized cross-over trial to define neurophysiological correlates of AV-101 N-methyl-D-aspartate receptor blockade in healthy veterans. Neuropsychopharmacology. 2021 03; 46(4):820-827. PMID: 33318635; PMCID: PMC8027791.
      Citations: 7     Fields:    Translation:Humans
    57. Mathew SJ. Is Testosterone an Effective Hormonal Therapy for Women With Antidepressant-Resistant Major Depression? Am J Psychiatry. 2020 10 01; 177(10):891-894. PMID: 32998547.
      Citations: 1     Fields:    Translation:Humans
    58. Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI. Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020 07; 25(7):1604. PMID: 30617276; PMCID: PMC8329695.
      Citations:    Fields:    
    59. Pizzagalli DA, Smoski M, Ang YS, Whitton AE, Sanacora G, Mathew SJ, Nurnberger J, Lisanby SH, Iosifescu DV, Murrough JW, Yang H, Weiner RD, Calabrese JR, Goodman W, Potter WZ, Krystal AD. Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS). Neuropsychopharmacology. 2020 09; 45(10):1656-1663. PMID: 32544925; PMCID: PMC7419512.
      Citations: 16     Fields:    Translation:Humans
    60. Papakostas GI, Salloum NC, Hock RS, Jha MK, Murrough JW, Mathew SJ, Iosifescu DV, Fava M. Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis. J Clin Psychiatry. 2020 05 26; 81(4). PMID: 32459407.
      Citations: 16     Fields:    Translation:Humans
    61. Kang GE, Patriquin MA, Nguyen H, Oh H, Rufino KA, Storch EA, Schanzer B, Mathew SJ, Salas R, Najafi B. Objective measurement of sleep, heart rate, heart rate variability, and physical activity in suicidality: A systematic review. J Affect Disord. 2020 08 01; 273:318-327. PMID: 32421619; PMCID: PMC7306422.
      Citations: 6     Fields:    Translation:Humans
    62. Freeman MP, Hock RS, Papakostas GI, Judge H, Cusin C, Mathew SJ, Sanacora G, Iosifescu DV, DeBattista C, Trivedi MH, Fava M. Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder. J Clin Psychopharmacol. 2020 May/Jun; 40(3):287-292. PMID: 32332464; PMCID: PMC7185034.
      Citations: 3     Fields:    Translation:Humans
    63. Iqbal SZ, Mathew SJ. Ketamine for depression clinical issues. Adv Pharmacol. 2020; 89:131-162. PMID: 32616205.
      Citations: 3     Fields:    Translation:Humans
    64. Krystal AD, Pizzagalli DA, Smoski M, Mathew SJ, Nurnberger J, Lisanby SH, Iosifescu D, Murrough JW, Yang H, Weiner RD, Calabrese JR, Sanacora G, Hermes G, Keefe RSE, Song A, Goodman W, Szabo ST, Whitton AE, Gao K, Potter WZ. A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating ?-opioid antagonism as a treatment for anhedonia. Nat Med. 2020 05; 26(5):760-768. PMID: 32231295; PMCID: PMC9949770.
      Citations: 37     Fields:    Translation:Humans
    65. Mathew SJ, Price RB. Ketamine Plus Motivational Enhancement Therapy: Leveraging a Rapid Effect to Promote Enduring Change. Am J Psychiatry. 2020 02 01; 177(2):107-109. PMID: 32008392.
      Citations:    Fields:    Translation:Humans
    66. Swann AC, Lijffijt M, O'Brien B, Mathew SJ. Impulsivity and Suicidal Behavior. Curr Top Behav Neurosci. 2020; 47:179-195. PMID: 32472429.
      Citations: 2     Fields:    Translation:Humans
    67. O'Brien B, Lee D, Swann AC, Mathew SJ, Lijffijt M. Psychotherapy for Mixed Depression and Mixed Mania. Psychiatr Clin North Am. 2020 03; 43(1):199-211. PMID: 32008685.
      Citations:    Fields:    Translation:Humans
    68. Lijffijt M, Green CE, Balderston N, Iqbal T, Atkinson M, Vo-Le B, Vo-Le B, O'Brien B, Grillon C, Swann AC, Mathew SJ. A Proof-of-Mechanism Study to Test Effects of the NMDA Receptor Antagonist Lanicemine on Behavioral Sensitization in Individuals With Symptoms of PTSD. Front Psychiatry. 2019; 10:846. PMID: 31920733; PMCID: PMC6923195.
      Citations: 5     
    69. Gazor A, Mathew SJ, Patriquin MA. Q-15 checks and 1:1 observations: Exacerbating a problem we are trying to solve? J Affect Disord. 2020 02 15; 263:552-554. PMID: 31780137.
      Citations:    Fields:    
    70. Schanzer B, Rivas-Grajales AM, Khan A, Mathew SJ. Novel investigational therapeutics for generalized anxiety disorder (GAD). Expert Opin Investig Drugs. 2019 Nov; 28(11):1003-1012. PMID: 31607187.
      Citations: 5     Fields:    Translation:HumansAnimals
    71. O'Brien B, Lijffijt M, Wells A, Swann AC, Mathew SJ. The Impact of Childhood Maltreatment on Intravenous Ketamine Outcomes for Adult Patients with Treatment-Resistant Depression. Pharmaceuticals (Basel). 2019 Sep 11; 12(3). PMID: 31514448; PMCID: PMC6789614.
      Citations: 7     
    72. Salloum NC, Fava M, Hock RS, Freeman MP, Flynn M, Hoeppner B, Cusin C, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Papakostas GI. Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. J Affect Disord. 2020 01 01; 260:131-139. PMID: 31494365; PMCID: PMC6803106.
      Citations: 10     Fields:    Translation:Humans
    73. O'Brien B, Green CE, Al-Jurdi R, Chang L, Lijffijt M, Iqbal S, Iqbal T, Swann AC, Mathew SJ. Bayesian adaptive randomization trial of intravenous ketamine for veterans with late-life, treatment-resistant depression. Contemp Clin Trials Commun. 2019 12; 16:100432. PMID: 31508531; PMCID: PMC6727003.
      Citations: 2     
    74. Sakurai H, Dording C, Yeung A, Foster S, Jain F, Chang T, Trinh NH, Bernard R, Boyden S, Iqbal SZ, Wilkinson ST, Mathew SJ, Mischoulon D, Fava M, Cusin C. Longer-term open-label study of adjunctive riluzole in treatment-resistant depression. J Affect Disord. 2019 11 01; 258:102-108. PMID: 31400624; PMCID: PMC6710149.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    75. Dakwar E, Nunes EV, Hart CL, Foltin RW, Mathew SJ, Carpenter KM, Choi CJJ, Basaraba CN, Pavlicova M, Levin FR. A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial. Am J Psychiatry. 2019 11 01; 176(11):923-930. PMID: 31230464.
      Citations: 20     Fields:    Translation:Humans
    76. Mathew SJ, Rivas-Grajales AM. "Does the opioid system block or enhance the antidepressant effects of ketamine?" Chronic Stress (Thousand Oaks). 2019 Jan-Dec/; 3. PMID: 31276079; PMCID: PMC6604658.
      Citations: 3     
    77. Gould F, Dunlop BW, Rosenthal JB, Iosifescu DV, Mathew SJ, Neylan TC, Rothbaum BO, Nemeroff CB, Harvey PD. Temporal Stability of Cognitive Functioning and Functional Capacity in Women with Posttraumatic Stress Disorder. Arch Clin Neuropsychol. 2019 Jun 01; 34(4):539-547. PMID: 30124744; PMCID: PMC6509556.
      Citations: 1     Fields:    Translation:Humans
    78. Hartwig EM, Rufino KA, Palmer CA, Shepard C, Alfano CA, Schanzer B, Mathew SJ, Patriquin MA. Trajectories of self-reported sleep disturbance across inpatient psychiatric treatment predict clinical outcome in comorbid major depressive disorder and generalized anxiety disorder. J Affect Disord. 2019 05 15; 251:248-255. PMID: 30953891.
      Citations: 5     Fields:    Translation:Humans
    79. Guo W, Machado-Vieira R, Mathew S, Murrough JW, Charney DS, Grunebaum M, Oquendo MA, Kadriu B, Akula N, Henter I, Yuan P, Merikangas K, Drevets W, Furey M, Mann JJ, McMahon FJ, Zarate CA, Shugart YY. Correction: Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. Transl Psychiatry. 2019 03 05; 9(1):108. PMID: 30837454; PMCID: PMC6401175.
      Citations:    Fields:    
    80. Jovanovic T, Duncan EJ, Kaye J, Garza K, Norrholm SD, Inslicht SS, Neylan TC, Mathew SJ, Iosifescu D, Rothbaum BO, Mayberg HS, Dunlop BW. Psychophysiological treatment outcomes: Corticotropin-releasing factor type 1 receptor antagonist increases inhibition of fear-potentiated startle in PTSD patients. Psychophysiology. 2020 01; 57(1):e13356. PMID: 30807663; PMCID: PMC6710166.
      Citations: 8     Fields:    Translation:Humans
    81. Lijffijt M, O'Brien B, Salas R, Mathew SJ, Swann AC. Interactions of immediate and long-term action regulation in the course and complications of bipolar disorder. Philos Trans R Soc Lond B Biol Sci. 2019 02 18; 374(1766):20180132. PMID: 30966917; PMCID: PMC6335464.
      Citations: 2     Fields:    Translation:Humans
    82. Wilkinson ST, Farmer C, Ballard ED, Mathew SJ, Grunebaum MF, Murrough JW, Sos P, Wang G, Gueorguieva R, Zarate CA. Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. Neuropsychopharmacology. 2019 06; 44(7):1233-1238. PMID: 30653192; PMCID: PMC6785710.
      Citations: 8     Fields:    Translation:Humans
    83. Freeman MP, Papakostas GI, Hoeppner B, Mazzone E, Judge H, Cusin C, Mathew S, Sanacora G, Iosifescu D, DeBattista C, Trivedi MH, Fava M. Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. J Psychiatr Res. 2019 03; 110:166-171. PMID: 30641350; PMCID: PMC6360121.
      Citations: 16     Fields:    Translation:Humans
    84. Salloum NC, Fava M, Freeman MP, Flynn M, Hoeppner B, Hock RS, Cusin C, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Papakostas GI. Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. Depress Anxiety. 2019 03; 36(3):235-243. PMID: 30597688.
      Citations: 6     Fields:    Translation:Humans
    85. Krystal AD, Pizzagalli DA, Mathew SJ, Sanacora G, Keefe R, Song A, Calabrese J, Goddard A, Goodman W, Lisanby SH, Smoski M, Weiner R, Iosifescu D, Nurnberger J, Szabo S, Murrough J, Shekhar A, Potter W. The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development. Nat Rev Drug Discov. 2018 12 28; 18(1):82-84. PMID: 30591715; PMCID: PMC6816017.
      Citations: 20     Fields:    Translation:Humans
    86. Mathew SJ, Wilkinson ST, Altinay M, Asghar-Ali A, Chang LC, Collins KA, Dale RM, Hu B, Krishnan K, Kellner CH, Malone DA, Murrough JW, Ostroff RB, Sanacora G, Shao M, Anand A. ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol. Contemp Clin Trials. 2019 02; 77:19-26. PMID: 30572160.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    87. Guo W, Machado-Vieira R, Mathew S, Murrough JW, Charney DS, Grunebaum M, Oquendo MA, Kadriu B, Akula N, Henter I, Yuan P, Merikangas K, Drevets W, Furey M, Mann JJ, McMahon FJ, Zarate CA, Shugart YY. Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. Transl Psychiatry. 2018 12 14; 8(1):280. PMID: 30552317; PMCID: PMC6294748.
      Citations: 10     Fields:    Translation:Humans
    88. Pape JC, Carrillo-Roa T, Rothbaum BO, Nemeroff CB, Czamara D, Zannas AS, Iosifescu D, Mathew SJ, Neylan TC, Mayberg HS, Dunlop BW, Binder EB. DNA methylation levels are associated with CRF1 receptor antagonist treatment outcome in women with post-traumatic stress disorder. Clin Epigenetics. 2018 11 03; 10(1):136. PMID: 30390684; PMCID: PMC6215613.
      Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
    89. Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020 07; 25(7):1592-1603. PMID: 30283029; PMCID: PMC6447473.
      Citations: 70     Fields:    Translation:Humans
    90. Wilkinson ST, Kiselycznyk C, Banasr M, Webler RD, Haile C, Mathew SJ. Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression. J Affect Disord. 2018 12 01; 241:514-518. PMID: 30153634; PMCID: PMC6140345.
      Citations: 8     Fields:    Translation:Humans
    91. Karp JF, Mathew S, Todtenkopf MS, Ehrich EW, Zubieta JK, Peci?a M. Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches. Mol Psychiatry. 2019 04; 24(4):576-587. PMID: 29955162; PMCID: PMC6310672.
      Citations: 42     Fields:    Translation:Humans
    92. Hodgins GE, Blommel JG, Dunlop BW, Iosifescu D, Mathew SJ, Neylan TC, Mayberg HS, Harvey PD. Placebo Effects Across Self-Report, Clinician Rating, and Objective Performance Tasks Among Women With Post-Traumatic Stress Disorder: Investigation of Placebo Response in a Pharmacological Treatment Study of Post-Traumatic Stress Disorder. J Clin Psychopharmacol. 2018 Jun; 38(3):200-206. PMID: 29505471; PMCID: PMC5903933.
      Citations: 3     Fields:    Translation:Humans
    93. Coplan JD, Lu D, El Sehamy AM, Tang C, Abdallah CG, Nemeroff CB, Owens MJ, Mathew SJ, Gorman JM, Jackowski AP. Early Life Stress Associated With Increased Striatal N-Acetyl-Aspartate: Cerebrospinal Fluid Corticotropin-Releasing Factor Concentrations, Hippocampal Volume, Body Mass and Behavioral Correlates. Chronic Stress (Thousand Oaks). 2018 Jan-Dec; 2. PMID: 29963652; PMCID: PMC6020138.
      Citations: 3     
    94. Coplan JD, Webler R, Gopinath S, Abdallah CG, Mathew SJ. Neurobiology of the dorsolateral prefrontal cortex in GAD: Aberrant neurometabolic correlation to hippocampus and relationship to anxiety sensitivity and IQ. J Affect Disord. 2018 03 15; 229:1-13. PMID: 29288871.
      Citations: 2     Fields:    Translation:Humans
    95. Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, Sos P, Wang G, Zarate CA, Sanacora G. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. Am J Psychiatry. 2018 02 01; 175(2):150-158. PMID: 28969441; PMCID: PMC5794524.
      Citations: 146     Fields:    Translation:Humans
    96. Abdallah CG, Averill CL, Salas R, Averill LA, Baldwin PR, Krystal JH, Mathew SJ, Mathalon DH. Prefrontal Connectivity and Glutamate Transmission: Relevance to Depression Pathophysiology and Ketamine Treatment. Biol Psychiatry Cogn Neurosci Neuroimaging. 2017 Oct; 2(7):566-574. PMID: 29034354; PMCID: PMC5635826.
      Citations: 48     Fields:    
    97. Dunlop BW, Binder EB, Iosifescu D, Mathew SJ, Neylan TC, Pape JC, Carrillo-Roa T, Green C, Kinkead B, Grigoriadis D, Rothbaum BO, Nemeroff CB, Mayberg HS. Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder. Biol Psychiatry. 2017 Dec 15; 82(12):866-874. PMID: 28793974; PMCID: PMC5683912.
      Citations: 36     Fields:    Translation:Humans
    98. Patriquin MA, Mathew SJ. The Neurobiological Mechanisms of Generalized Anxiety Disorder and Chronic Stress. Chronic Stress (Thousand Oaks). 2017 Jan-Dec; 1. PMID: 29503978; PMCID: PMC5832062.
      Citations: 17     
    99. Mathew SJ, Gueorguieva R, Brandt C, Fava M, Sanacora G. A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder. Neuropsychopharmacology. 2017 Dec; 42(13):2567-2574. PMID: 28553836; PMCID: PMC5686483.
      Citations: 9     Fields:    Translation:Humans
    100. Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF, Summergrad P, Nemeroff CB, American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatm. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry. 2017 Apr 01; 74(4):399-405. PMID: 28249076.
      Citations: 111     Fields:    Translation:Humans
    101. Murrough JW, Abdallah CG, Mathew SJ. Targeting glutamate signalling in depression: progress and prospects. Nat Rev Drug Discov. 2017 Jul; 16(7):472-486. PMID: 28303025.
      Citations: 131     Fields:    Translation:HumansAnimalsCells
    102. Abdallah CG, Salas R, Gupta S, Mao X, Coplan JD, Shungu DC, Mathew SJ, Jackowski A, Sato JR. The Nucleus Accumbens and Ketamine Treatment in Major Depressive Disorder. Neuropsychopharmacology. 2017 Jul; 42(8):1739-1746. PMID: 28272497; PMCID: PMC5518908.
      Citations: 38     Fields:    Translation:Humans
    103. Mathew SJ, Lijffijt M. Neurometabolic Abnormalities in Treatment-Resistant Depression. Am J Psychiatry. 2017 01 01; 174(1):3-5. PMID: 28041002.
      Citations: 1     Fields:    Translation:Humans
    104. Sanacora G, Johnson MR, Khan A, Atkinson SD, Riesenberg RR, Schronen JP, Burke MA, Zajecka JM, Barra L, Su HL, Posener JA, Bui KH, Quirk MC, Piser TM, Mathew SJ, Pathak S. Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study. Neuropsychopharmacology. 2017 Mar; 42(4):844-853. PMID: 27681442; PMCID: PMC5312066.
      Citations: 50     Fields:    Translation:HumansCTClinical Trials
    105. Lijffijt M, Lane SD, Mathew SJ, Stanford MS, Swann AC. Heightened early-attentional stimulus orienting and impulsive action in men with antisocial personality disorder. Eur Arch Psychiatry Clin Neurosci. 2017 Oct; 267(7):697-707. PMID: 27662886.
      Citations: 1     Fields:    Translation:Humans
    106. Sharp C, Fowler JC, Salas R, Nielsen D, Allen J, Oldham J, Kosten T, Mathew S, Madan A, Frueh BC, Fonagy P. Operationalizing NIMH Research Domain Criteria (RDoC) in naturalistic clinical settings. Bull Menninger Clin. 2016; 80(3):187-212. PMID: 27583809.
      Citations: 2     Fields:    Translation:Humans
    107. Coplan JD, Kolavennu V, Abdallah CG, Mathew SJ, Perera TD, Pantol G, Carpenter D, Tang C. Patterns of anterior versus posterior white matter fractional anistotropy concordance in adult nonhuman primates: Effects of early life stress. J Affect Disord. 2016 Mar 01; 192:167-75. PMID: 26735328; PMCID: PMC6129259.
      Citations: 4     Fields:    Translation:Animals
    108. Raparia E, Coplan JD, Abdallah CG, Hof PR, Mao X, Shungu DC, Mathew SJ. Impact of childhood emotional abuse on neocortical neurometabolites and complex emotional processing in patients with generalized anxiety disorder. J Affect Disord. 2016 Jan 15; 190:414-423. PMID: 26551399.
      Citations: 3     Fields:    Translation:Humans
    109. Al Jurdi RK, Swann A, Mathew SJ. Psychopharmacological Agents and Suicide Risk Reduction: Ketamine and Other Approaches. Curr Psychiatry Rep. 2015 Oct; 17(10):81. PMID: 26307033.
      Citations: 9     Fields:    Translation:Humans
    110. Torbeyns A, Hennicken D, Zheng M, Dunlop BW, Mathew SJ, Khan A, Weisler R, Nelson C, Shelton R, Thase ME, Lane R, Bhagwagar Z. Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression: Results From 2 Randomized, Double-Blind Studies. J Clin Psychopharmacol. 2015 Aug; 35(4):454-9. PMID: 25961781.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    111. Abdallah CG, Mao X, Kang G, Cheema R, Coplan JD, Mathew SJ, Shungu DC, Jackowski A, Sato JR. Prefrontal cortical GABA abnormalities are associated with reduced hippocampal volume in major depressive disorder. Eur Neuropsychopharmacol. 2015 Aug; 25(8):1082-90. PMID: 25983019; PMCID: PMC4526377.
      Citations: 22     Fields:    Translation:Humans
    112. Murrough JW, Burdick KE, Levitch CF, Perez AM, Brallier JW, Chang LC, Foulkes A, Charney DS, Mathew SJ, Iosifescu DV. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Neuropsychopharmacology. 2015 Mar 13; 40(5):1084-90. PMID: 25374095; PMCID: PMC4367458.
      Citations: 36     Fields:    Translation:Humans
    113. Price RB, Mathew SJ. Does ketamine have anti-suicidal properties? Current status and future directions. CNS Drugs. 2015 Mar; 29(3):181-8. PMID: 25715884; PMCID: PMC4380583.
      Citations: 22     Fields:    Translation:HumansAnimals
    114. Wan LB, Levitch CF, Perez AM, Brallier JW, Iosifescu DV, Chang LC, Foulkes A, Mathew SJ, Charney DS, Murrough JW. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2015 Mar; 76(3):247-52. PMID: 25271445.
      Citations: 59     Fields:    Translation:Humans
    115. DeWilde KE, Levitch CF, Murrough JW, Mathew SJ, Iosifescu DV. The promise of ketamine for treatment-resistant depression: current evidence and future directions. Ann N Y Acad Sci. 2015 May; 1345:47-58. PMID: 25649308; PMCID: PMC4447578.
      Citations: 24     Fields:    Translation:Humans
    116. Ridgewell C, Bray A, Curtis K, Velasquez K, Baldwin PR, Fowler JC, Mathew SJ, Salas R. Enhanced Olfactory Cortex Connectivity in a Patient With PTSD With Olfactory Hallucinations. J Neuropsychiatry Clin Neurosci. 2015; 27(2):e170-1. PMID: 25923873.
      Citations: 2     Fields:    Translation:Humans
    117. Coplan J, Singh D, Gopinath S, Mathew SJ, Bulbena A. A Novel Anxiety and Affective Spectrum Disorder of Mind and Body-The ALPIM (Anxiety-Laxity-Pain-Immune-Mood) Syndrome: A Preliminary Report. J Neuropsychiatry Clin Neurosci. 2015; 27(2):93-103. PMID: 25923849.
      Citations: 2     Fields:    Translation:Humans
    118. Coplan JD, Fulton SL, Reiner W, Panthangi V, Perera TD, Gorman JM, Huang YY, Tang CY, Hof PR, Kaffman A, Dwork AJ, Mathew SJ, Kaufman J, Mann JJ, Jackowski A. Elevated cerebrospinal fluid 5-hydroxyindoleacetic acid in macaques following early life stress and inverse association with hippocampal volume: preliminary implications for serotonin-related function in mood and anxiety disorders. Front Behav Neurosci. 2014; 8:440. PMID: 25566007; PMCID: PMC4274982.
      Citations: 9     
    119. Coplan JD, Fathy HM, Tang CY, Perera TD, Mathew SJ, Martinez J, Abdallah CG, Dwork AJ, Pantol G, Carpenter D, Gorman JM, Nemeroff CB, Owens MJ, Kaffman A, Kaufman J, Jackowski AP. Early life stress and macaque amygdala hypertrophy: preliminary evidence for a role for the serotonin transporter gene. Front Behav Neurosci. 2014; 8:342. PMID: 25339875; PMCID: PMC4186477.
      Citations: 16     
    120. Abdallah CG, Salas R, Baldwin P, Mathew SJ, Jackowski A, Sato JR. Hippocampal volume and the rapid antidepressant effect of ketamine. J Psychopharmacol. 2015 May; 29(5):591-5. PMID: 25122038; PMCID: PMC4852551.
      Citations: 29     Fields:    Translation:Humans
    121. Dunlop BW, Rothbaum BO, Binder EB, Duncan E, Harvey PD, Jovanovic T, Kelley ME, Kinkead B, Kutner M, Iosifescu DV, Mathew SJ, Neylan TC, Kilts CD, Nemeroff CB, Mayberg HS. Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial. Trials. 2014 Jun 21; 15:240. PMID: 24950747; PMCID: PMC4082482.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    122. Kaye JL, Dunlop BW, Iosifescu DV, Mathew SJ, Kelley ME, Harvey PD. Cognition, functional capacity, and self-reported disability in women with posttraumatic stress disorder: examining the convergence of performance-based measures and self-reports. J Psychiatr Res. 2014 Oct; 57:51-7. PMID: 24974001; PMCID: PMC4127348.
      Citations: 12     Fields:    Translation:Humans
    123. Lapidus KA, Gabbay V, Mao X, Johnson A, Murrough JW, Mathew SJ, Shungu DC. In vivo (1)H MRS study of potential associations between glutathione, oxidative stress and anhedonia in major depressive disorder. Neurosci Lett. 2014 May 21; 569:74-9. PMID: 24704328; PMCID: PMC4108847.
      Citations: 22     Fields:    Translation:Humans
    124. Price RB, Iosifescu DV, Murrough JW, Chang LC, Al Jurdi RK, Iqbal SZ, Soleimani L, Charney DS, Foulkes AL, Mathew SJ. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety. 2014 Apr; 31(4):335-43. PMID: 24668760; PMCID: PMC4112410.
      Citations: 114     Fields:    Translation:Humans
    125. Coplan JD, Fathy HM, Abdallah CG, Ragab SA, Kral JG, Mao X, Shungu DC, Mathew SJ. Reduced hippocampal N-acetyl-aspartate (NAA) as a biomarker for overweight. Neuroimage Clin. 2014; 4:326-35. PMID: 24501701; PMCID: PMC3913836.
      Citations: 10     Fields:    Translation:HumansCells
    126. Mathew SJ. Glycine transporter-I inhibitors: a new class of antidepressant? Biol Psychiatry. 2013 Nov 15; 74(10):710-1. PMID: 24144323.
      Citations: 3     Fields:    Translation:HumansAnimals
    127. Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah A, Charney DS, Mathew SJ. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013 Oct; 170(10):1134-42. PMID: 23982301; PMCID: PMC3992936.
      Citations: 345     Fields:    Translation:Humans
    128. Murrough JW, Wan LB, Iacoviello B, Collins KA, Solon C, Glicksberg B, Perez AM, Mathew SJ, Charney DS, Iosifescu DV, Burdick KE. Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. Psychopharmacology (Berl). 2013 Sep 11. PMID: 24022236; PMCID: PMC3952038.
      Citations: 34     Fields:    
    129. Chang LC, Raty SR, Ortiz J, Bailard NS, Mathew SJ. The emerging use of ketamine for anesthesia and sedation in traumatic brain injuries. CNS Neurosci Ther. 2013 Jun; 19(6):390-5. PMID: 23480625; PMCID: PMC3663879.
      Citations: 25     Fields:    Translation:Humans
    130. Abdallah CG, Coplan JD, Jackowski A, Mao X, Shungu DC, Mathew SJ, Sato JR. Riluzole effect on occipital cortex: a structural and spectroscopy pilot study. Neurosci Lett. 2012 Nov 14; 530(1):103-7. PMID: 23043888; PMCID: PMC3490039.
      Citations: 7     Fields:    Translation:Humans
    131. Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, Collins KA, Mathew SJ, Charney DS, Iosifescu DV. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013 Aug 15; 74(4):250-6. PMID: 22840761; PMCID: PMC3725185.
      Citations: 251     Fields:    Translation:HumansCTClinical Trials
    132. Abdallah CG, Coplan JD, Jackowski A, Mao X, Shungu DC, Mathew SJ, Sato JR. A pilot study of hippocampal volume and N-acetylaspartate (NAA) as response biomarkers in riluzole-treated patients with GAD. Eur Neuropsychopharmacol. 2013 Apr; 23(4):276-84. PMID: 22739126; PMCID: PMC3473175.
      Citations: 29     Fields:    Translation:Humans
    133. Aan Het Rot M, Zarate CA, Charney DS, Mathew SJ. Ketamine for depression: where do we go from here? Biol Psychiatry. 2012 Oct 01; 72(7):537-47. PMID: 22705040; PMCID: PMC3438349.
      Citations: 121     Fields:    Translation:HumansAnimals
    134. Mathew SJ, Shah A, Lapidus K, Clark C, Jarun N, Ostermeyer B, Murrough JW. Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs. 2012 Mar 01; 26(3):189-204. PMID: 22303887; PMCID: PMC3677048.
      Citations: 66     Fields:    Translation:HumansCells
    135. Anand A, Gunn AD, Barkay G, Karne HS, Nurnberger JI, Mathew SJ, Ghosh S. Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial. Bipolar Disord. 2012 Feb; 14(1):64-70. PMID: 22329473.
      Citations: 27     Fields:    Translation:Humans
    136. Coplan JD, Hodulik S, Mathew SJ, Mao X, Hof PR, Gorman JM, Shungu DC. The Relationship between Intelligence and Anxiety: An Association with Subcortical White Matter Metabolism. Front Evol Neurosci. 2011; 3:8. PMID: 22347183; PMCID: PMC3269637.
      Citations: 6     
    137. Shungu DC, Weiduschat N, Murrough JW, Mao X, Pillemer S, Dyke JP, Medow MS, Natelson BH, Stewart JM, Mathew SJ. Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. NMR Biomed. 2012 Sep; 25(9):1073-87. PMID: 22281935; PMCID: PMC3896084.
      Citations: 81     Fields:    Translation:Humans
    138. Coplan JD, Abdallah CG, Mathew SJ, Shungu DC, Mao X, Smith EL, Kaufman D, Gorman JM, Owens MJ, Nemeroff CB, Banerji MA, Rosenblum LA, Kral JG. Metabolic syndrome and neurometabolic asymmetry of hippocampus in adult bonnet monkeys. Physiol Behav. 2011 Jul 06; 103(5):535-9. PMID: 21459102; PMCID: PMC3107881.
      Citations: 2     Fields:    Translation:Animals
    139. Perera TD, Abdallah CG, Garrido G, Tang CY, Martinez J, Mathew SJ, Gorman JM, Rosenblum LA, Smith EL, Dwork AJ, Shungu DC, Kaffman A, Gelernter J, Coplan JD, Kaufman J, Jackowski A. Early-life stress, corpus callosum development, hippocampal volumetrics, and anxious behavior in male nonhuman primates. Psychiatry Res. 2011 Apr 30; 192(1):37-44. PMID: 21377844; PMCID: PMC4090111.
      Citations: 43     Fields:    Translation:Animals
    140. Feder A, Skipper J, Blair JR, Buchholz K, Mathew SJ, Schwarz M, Doucette JT, Alonso A, Collins KA, Neumeister A, Charney DS. Tryptophan depletion and emotional processing in healthy volunteers at high risk for depression. Biol Psychiatry. 2011 Apr 15; 69(8):804-7. PMID: 21377656; PMCID: PMC3941748.
      Citations: 15     Fields:    Translation:Humans
    141. Murrough JW, Perez AM, Mathew SJ, Charney DS. A case of sustained remission following an acute course of ketamine in treatment-resistant depression. J Clin Psychiatry. 2011 Mar; 72(3):414-5. PMID: 21450159.
      Citations: 13     Fields:    Translation:Humans
    142. Mathew SJ, Vythilingam M, Murrough JW, Zarate CA, Feder A, Luckenbaugh DA, Kinkead B, Parides MK, Trist DG, Bani MS, Bettica PU, Ratti EM, Charney DS. A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. Eur Neuropsychopharmacol. 2011 Mar; 21(3):221-9. PMID: 21194898; PMCID: PMC3478767.
      Citations: 20     Fields:    Translation:Humans
    143. Coplan JD, Mathew SJ, Abdallah CG, Mao X, Kral JG, Smith EL, Rosenblum LA, Perera TD, Dwork AJ, Hof PR, Gorman JM, Shungu DC. Early-life stress and neurometabolites of the hippocampus. Brain Res. 2010 Oct 28; 1358:191-9. PMID: 20713023; PMCID: PMC2988576.
      Citations: 10     Fields:    Translation:Animals
    144. Krystal JH, Mathew SJ, D'Souza DC, Garakani A, Gunduz-Bruce H, Charney DS. Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs. 2010 Aug; 24(8):669-93. PMID: 20658799.
      Citations: 75     Fields:    Translation:HumansAnimals
    145. Murrough JW, Mao X, Collins KA, Kelly C, Andrade G, Nestadt P, Levine SM, Mathew SJ, Shungu DC. Increased ventricular lactate in chronic fatigue syndrome measured by 1H MRS imaging at 3.0 T. II: comparison with major depressive disorder. NMR Biomed. 2010 Jul; 23(6):643-50. PMID: 20661876.
      Citations: 47     Fields:    Translation:Humans
    146. Coplan JD, Abdallah CG, Tang CY, Mathew SJ, Martinez J, Hof PR, Smith EL, Dwork AJ, Perera TD, Pantol G, Carpenter D, Rosenblum LA, Shungu DC, Gelernter J, Kaffman A, Jackowski A, Kaufman J, Gorman JM. The role of early life stress in development of the anterior limb of the internal capsule in nonhuman primates. Neurosci Lett. 2010 Aug 16; 480(2):93-6. PMID: 20541590; PMCID: PMC2951885.
      Citations: 28     Fields:    Translation:Animals
    147. Abdallah CG, Tang CY, Mathew SJ, Martinez J, Hof PR, Perera TD, Shungu DC, Gorman JM, Coplan JD. Diffusion tensor imaging in studying white matter complexity: a gap junction hypothesis. Neurosci Lett. 2010 May 21; 475(3):161-4. PMID: 20371267; PMCID: PMC2862850.
      Citations: 3     Fields:    Translation:AnimalsCells
    148. aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010 Jan 15; 67(2):139-45. PMID: 19897179.
      Citations: 234     Fields:    Translation:HumansCTClinical Trials
    149. Price RB, Nock MK, Charney DS, Mathew SJ. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009 Sep 01; 66(5):522-6. PMID: 19545857; PMCID: PMC2935847.
      Citations: 235     Fields:    Translation:HumansCTClinical Trials
    150. Mathew SJ, Mao X, Keegan KA, Levine SM, Smith EL, Heier LA, Otcheretko V, Coplan JD, Shungu DC. Ventricular cerebrospinal fluid lactate is increased in chronic fatigue syndrome compared with generalized anxiety disorder: an in vivo 3.0 T (1)H MRS imaging study. NMR Biomed. 2009 Apr; 22(3):251-8. PMID: 18942064.
      Citations: 45     Fields:    Translation:Humans
    151. Mathew SJ, Murrough JW, aan het Rot M, Collins KA, Reich DL, Charney DS. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol. 2010 Feb; 13(1):71-82. PMID: 19288975; PMCID: PMC3883127.
      Citations: 102     Fields:    Translation:HumansPHPublic Health
    152. aan het Rot M, Mathew SJ, Charney DS. Neurobiological mechanisms in major depressive disorder. CMAJ. 2009 Feb 03; 180(3):305-13. PMID: 19188629; PMCID: PMC2630359.
      Citations: 113     Fields:    Translation:Humans
    153. Mathew SJ, Charney DS. Publication bias and the efficacy of antidepressants. Am J Psychiatry. 2009 Feb; 166(2):140-5. PMID: 19188290.
      Citations: 19     Fields:    Translation:Humans
    154. Price RB, Shungu DC, Mao X, Nestadt P, Kelly C, Collins KA, Murrough JW, Charney DS, Mathew SJ. Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder. Biol Psychiatry. 2009 May 01; 65(9):792-800. PMID: 19058788; PMCID: PMC2934870.
      Citations: 90     Fields:    Translation:Humans
    155. Mathew SJ, Garakani A, Reinhard JF, Oshana S, Donahue S. Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study. Clin Ther. 2008 Sep; 30(9):1658-66. PMID: 18840371.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    156. Mathew SJ, Price RB, Charney DS. Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics. Am J Med Genet C Semin Med Genet. 2008 May 15; 148C(2):89-98. PMID: 18412102.
      Citations: 48     Fields:    Translation:HumansAnimals
    157. Mathew S, Charney D. Anxiety and depression: leading edge of therapy. Mt Sinai J Med. 2008 May-Jun; 75(3):171-3. PMID: 18704975.
      Citations: 2     Fields:    Translation:Humans
    158. Dumitriu D, Collins K, Alterman R, Mathew SJ. Neurostimulatory therapeutics in management of treatment-resistant depression with focus on deep brain stimulation. Mt Sinai J Med. 2008 May-Jun; 75(3):263-75. PMID: 18704979.
      Citations: 4     Fields:    Translation:Humans
    159. Hoffman EJ, Mathew SJ. Anxiety disorders: a comprehensive review of pharmacotherapies. Mt Sinai J Med. 2008 May-Jun; 75(3):248-62. PMID: 18704983.
      Citations: 40     Fields:    Translation:Humans
    160. Rickels K, Mathew S, Banov MD, Zimbroff DL, Oshana S, Parsons EC, Donahue SR, Kauffman M, Iyer GR, Reinhard JF. Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2008 Apr; 28(2):235-9. PMID: 18344738.
      Citations: 2     Fields:    Translation:Humans
    161. Mathew SJ, Manji HK, Charney DS. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug; 33(9):2080-92. PMID: 18172433.
      Citations: 61     Fields:    Translation:HumansAnimalsCells
    162. Mathew SJ. Treatment-resistant depression: recent developments and future directions. Depress Anxiety. 2008; 25(12):989-92. PMID: 19058261; PMCID: PMC2933841.
      Citations: 13     Fields:    Translation:Humans
    163. Mathew SJ, Price RB, Mao X, Smith EL, Coplan JD, Charney DS, Shungu DC. Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder. Biol Psychiatry. 2008 May 01; 63(9):891-8. PMID: 18028881; PMCID: PMC2385784.
      Citations: 23     Fields:    Translation:Humans
    164. Amiel JM, Mathew SJ. Glutamate and anxiety disorders. Curr Psychiatry Rep. 2007 Aug; 9(4):278-83. PMID: 17880858.
      Citations: 16     Fields:    Translation:Humans
    165. Garakani A, Mathew SJ, Charney DS. Neurobiology of anxiety disorders and implications for treatment. Mt Sinai J Med. 2006 Nov; 73(7):941-9. PMID: 17195879.
      Citations: 45     Fields:    Translation:HumansAnimals
    166. Coplan JD, Smith EL, Altemus M, Mathew SJ, Perera T, Kral JG, Gorman JM, Owens MJ, Nemeroff CB, Rosenblum LA. Maternal-infant response to variable foraging demand in nonhuman primates: effects of timing of stressor on cerebrospinal fluid corticotropin-releasing factor and circulating glucocorticoid concentrations. Ann N Y Acad Sci. 2006 Jul; 1071:525-33. PMID: 16891612.
      Citations: 14     Fields:    Translation:Animals
    167. Coplan JD, Mathew SJ, Mao X, Smith EL, Hof PR, Coplan PM, Rosenblum LA, Gorman JM, Shungu DC. Decreased choline and creatine concentrations in centrum semiovale in patients with generalized anxiety disorder: relationship to IQ and early trauma. Psychiatry Res. 2006 Jun 30; 147(1):27-39. PMID: 16797939.
      Citations: 15     Fields:    Translation:Humans
    168. Mathew SJ, Ho S. Etiology and neurobiology of social anxiety disorder. J Clin Psychiatry. 2006; 67 Suppl 12:9-13. PMID: 17092190.
      Citations: 16     Fields:    Translation:Humans
    169. Mathew SJ, Amiel JM, Coplan JD, Fitterling HA, Sackeim HA, Gorman JM. Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry. 2005 Dec; 162(12):2379-81. PMID: 16330605.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    170. Mathew SJ, Keegan K, Smith L. Glutamate modulators as novel interventions for mood disorders. Braz J Psychiatry. 2005 Sep; 27(3):243-8. PMID: 16224615.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    171. Coplan JD, Altemus M, Mathew SJ, Smith EL, Sharf B, Coplan PM, Kral JG, Gorman JM, Owens MJ, Nemeroff CB, Rosenblum LA. Synchronized maternal-infant elevations of primate CSF CRF concentrations in response to variable foraging demand. CNS Spectr. 2005 Jul; 10(7):530-6. PMID: 16155510.
      Citations: 20     Fields:    Translation:Animals
    172. Feder A, Coplan JD, Goetz RR, Mathew SJ, Pine DS, Dahl RE, Ryan ND, Greenwald S, Weissman MM. Twenty-four-hour cortisol secretion patterns in prepubertal children with anxiety or depressive disorders. Biol Psychiatry. 2004 Aug 01; 56(3):198-204. PMID: 15271589.
      Citations: 25     Fields:    Translation:Humans
    173. Mathew SJ, Mao X, Coplan JD, Smith EL, Sackeim HA, Gorman JM, Shungu DC. Dorsolateral prefrontal cortical pathology in generalized anxiety disorder: a proton magnetic resonance spectroscopic imaging study. Am J Psychiatry. 2004 Jun; 161(6):1119-21. PMID: 15169704.
      Citations: 25     Fields:    Translation:Humans
    174. Mathew SJ, Shungu DC, Mao X, Smith EL, Perera GM, Kegeles LS, Perera T, Lisanby SH, Rosenblum LA, Gorman JM, Coplan JD. A magnetic resonance spectroscopic imaging study of adult nonhuman primates exposed to early-life stressors. Biol Psychiatry. 2003 Oct 01; 54(7):727-35. PMID: 14512213.
      Citations: 31     Fields:    Translation:Animals
    175. Mathew SJ, Coplan JD, Goetz RR, Feder A, Greenwald S, Dahl RE, Ryan ND, Mann JJ, Weissman MM. Differentiating depressed adolescent 24 h cortisol secretion in light of their adult clinical outcome. Neuropsychopharmacology. 2003 Jul; 28(7):1336-43. PMID: 12784120.
      Citations: 22     Fields:    Translation:Humans
    176. Kent JM, Mathew SJ, Gorman JM. Molecular targets in the treatment of anxiety. Biol Psychiatry. 2002 Nov 15; 52(10):1008-30. PMID: 12437941.
      Citations: 35     Fields:    Translation:HumansAnimals
    177. Mathew SJ, Coplan JD, Smith EL, Scharf BA, Owens MJ, Nemeroff CB, Mann JJ, Gorman JM, Rosenblum LA. Cerebrospinal fluid concentrations of biogenic amines and corticotropin-releasing factor in adolescent non-human primates as a function of the timing of adverse early rearing. Stress. 2002 Sep; 5(3):185-93. PMID: 12186681.
      Citations: 17     Fields:    Translation:Animals
    178. Gorman JM, Mathew S, Coplan J. Neurobiology of early life stress: nonhuman primate models. Semin Clin Neuropsychiatry. 2002 Apr; 7(2):96-103. PMID: 11953933.
      Citations: 10     Fields:    Translation:Animals
    MATHEW's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (396)
    Explore
    _
    Co-Authors (35)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _